Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate ABX-1431 for the Treatment of Neuropathic Pain

Next Previous
Trial Profile

A Phase 2 Study to Evaluate ABX-1431 for the Treatment of Neuropathic Pain

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elcubragistat (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Abide Therapeutics; Lundbeck A/S

Most Recent Events

  • 29 May 2019 Lundbeck A/S after having received customary regulatory approvals has acquired Abide Therapeutics Inc.
  • 30 Jan 2019 New trial record
  • 24 Jan 2019 According to an Abide Therapeutics media release, the company expect to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration later this year, for this planned phase II trial in neuropathic pain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top